This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Celldex Might Be The Next Alexion? Buy Buy Buy!!

CLDX Chart CLDX data by YCharts

NEEDHAM, MASS. ( TheStreet) -- Celldex Therapeutics (CLDX - Get Report) shares have surged 50 percent in the past two weeks because some investors are speculating the company could become (or is becoming) the next great ultra-orphan drug stock.

Investors love ultra-orphan diseases because the drugs that treat them can be priced sky high without pushback from insurance companies. The Celldex orphan disease drug candidate is known as CDX-1135 and is being developed as a treatment for dense deposit disease (DDD), a rare kidney disorder that affects approximately two people out of every 1 million worldwide.

Celldex announced dosing of the first DDD patient in a small, five-patient pilot trial of CDX-1135 on July 1. Results are expected before the end of the year.

Why would such a small trial cause investor to jump headfirst into Celldex?

Check out what Oppenheimer analyst Boris Peaker said on June 21 about CDX-1135 on June 21, right before Celldex shares took off:

While CDX-1135 remains in the early stages of development, we believe positive pilot results may lead some investors to compare CDX-1135 to other complement modulating drugs like Soliris from Alexion Pharmaceuticals (ALXN - Get Report). However, we think that these comparisons are premature given the lack of clinical data. For reference, Soliris is approved in the US for paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), and is being evaluated for a number of additional indications. Sales of the drug in 2012 topped $1.1B, and we note that Soliris is not currently being studied in DDD despite completion of Phase I testing that showed improvement in symptoms.

Peaker is probably right when he says it's a bit early to compare Celldex to Alexion, but not for many speculators in this raging biotech bull market.

Celldex is taking a breather today, down 4% to $20.36., but over the past two weeks, no bio-pharma stock has been hotter with the exception of Onyx Pharmaceuticals (ONXX), which surged because of the Amgen (AMGN) takeover attempt.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ONXX $0.00 0.00%
ALXN $164.31 0.00%
CLDX $11.74 0.00%
AAPL $109.50 0.00%
FB $92.47 0.00%


Chart of I:DJI
DOW 17,050.75 +138.46 0.82%
S&P 500 2,013.43 +15.91 0.80%
NASDAQ 4,810.7880 +19.6360 0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs